# NIH Reporter #4UH3CA290241-03

CD28-KITv CAR T cells with PD-1 dominant negative receptor

**Recipient:** Sloan-Kettering Inst Can Research

**Award Amount:** $3,047,785.00
**Ceiling:** $3,047,785.00

**Awarded:** May 07, 2026

**Identifier:** 4UH3CA290241-03

This award supports the development of advanced CAR T-cell therapy for solid tumors using CD28-costimulated CARs, PD-1 dominant negative receptor checkpoint blockade, and c-KIT mutation co-stimulation, combined with targeted radiation therapy to enhance tumor infiltration and treatment efficacy.

### Description

The project involves translating CD28-costimulated CARs targeting mesothelin, employing tumor-specific checkpoint blockade via PD1DNR, and utilizing a c-KIT mutation (KITv) as a co-stimulatory domain. The strategy includes non-ablative, tumor-targeted radiation therapy to promote tumor infiltration and systemic delivery of next-generation CAR T cells.

[View original record](https://reporter.nih.gov/search/IgE1H2ioLUOz0qmA4MDg0Q/project-details/11457454)